<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02667327</url>
  </required_header>
  <id_info>
    <org_study_id>2015-DFU-301</org_study_id>
    <nct_id>NCT02667327</nct_id>
    <nct_alias>NCT02666131</nct_alias>
  </id_info>
  <brief_title>A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer</brief_title>
  <official_title>A Phase 3, Randomized, Double-blind, Parallel-group, Vehicle Controlled, Multicenter Study of the Efficacy and Safety of Granexin Gel in the Treatment of Diabetic Foot Ulcer (GAIT 1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FirstString Research, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FirstString Research, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Granexin gel is safe and effective in the
      treatment of diabetic foot ulcers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DFU patients will undergo a one week screening period and those with changes in ulcer size of
      less than 30% will be eligible for randomization providing all other criteria are met.
      Participants enrolled in the study will receive treatment based on randomization into 1 of 3
      treatment arms for up to 12 weeks. The participants will have an additional 12 week follow-up
      period beyond the treatment period to assess durability of wound closure.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor Decision (No safety or efficacy concerns)
  </why_stopped>
  <start_date type="Actual">November 21, 2018</start_date>
  <completion_date type="Actual">May 27, 2020</completion_date>
  <primary_completion_date type="Actual">May 27, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of complete wound closure at Week 12 based on investigator assessment</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time in days to first complete wound closure of the target ulcer based on investigator assessment over the 12 week treatment period</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Diabetic Foot Ulcers</condition>
  <arm_group>
    <arm_group_label>Granexin gel plus Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Granexin gel is comprised of 100 μM aCT1 peptide plus hydroxyethyl cellulose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle gel plus Standard of Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle gel is hydroxyethyl cellulose without active pharmaceutical ingredient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care includes cleaning and irrigating ulcer, non-surgical debridement, pain management, ulcer dressing, off-loading, and nutritional assessment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granexin gel</intervention_name>
    <description>Granexin gel contains active pharmaceutical ingredient, aCT1 peptide, for topical application to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.</description>
    <arm_group_label>Granexin gel plus Standard of Care</arm_group_label>
    <other_name>Granexin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle gel</intervention_name>
    <description>The vehicle gel formulation is hydroxyethyl cellulose that does not contain the active aCT1 peptide. Vehicle gel will be applied topically to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.</description>
    <arm_group_label>Vehicle gel plus Standard of Care</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Both male and female participants may participate in the study.

        To be eligible for entry into this study, a patient must meet all of the following
        Inclusion criteria:

          1. Age 18 years or older

          2. Established diagnosis of diabetes mellitus (type I or II)

          3. Glycosylated hemoglobin (HbA1c) value &lt; 12.0% at the screening visit

          4. Diagnosis of neuropathic foot ulcer by 10g monofilament test, tuning fork (128 Hz), or
             cotton wisp

          5. Designated foot ulcer meets the following criteria at both the screening and baseline
             visits:

               1. Present for at least 4 weeks

               2. Full-thickness cutaneous ulcer below the ankle surface

               3. University of Texas grade A1

               4. Wound area (after debridement) 1 to 40.0 cm2

               5. Viable, granulating wound (investigator discretion)

          6. Ankle brachial index ≤ 0.7 at both the screening and baseline visits. If the ABI is
             &gt;1.30, one of the following confirmatory tests must be performed for the patient to be
             considered eligible:

               1. Does Not have a monophonic or biphasic flow (with the loss of reverse flow) in
                  the artery of the foot with the target ulcer via doppler waveform analysis of the
                  dorsalis pedis and posterior tibial arteries, as determined by standard practices
                  of the investigator and the site.

               2. Transcutaneous oxygen pressure (TcPO2) at the foot &gt;40 mmHg

             Additionally, patients must meet all other protocol-defined eligibility criteria.

          7. Signed informed consent

          8. Female patients of childbearing potential must have a negative pregnancy test at
             screening and must agree to use hormonal contraceptive, intrauterine device, diaphragm
             with spermicide, condom with spermicide, or abstinence throughout until 2 weeks after
             the last administration of investigational product. Male patients must also agree to
             use contraception such as a condom.

        Exclusion Criteria:

        Patients will not be eligible for enrollment in the study if they meet any of the exclusion
        criterial listed below:

          1. Change (decrease or increase) in size of the designated target ulcer by ≥ 30% during
             the 7-day screening period

          2. Cannot tolerate the off-loading methods or cannot comply with study related procedures

          3. Has an ulcer that meets any of the following criteria:

               1. Shows signs of severe clinical infection, defined as pus oozing from the ulcer
                  site

               2. Requires surgical debridement

               3. Is positive for β-hemolytic streptococci upon culture performed prior to
                  screening debridement procedure

               4. Has &gt; 50% slough, significant necrotic tissue, bone, tendon, or capsule exposure

               5. Is highly exuding (i.e., requires daily change of dressing)

          4. Requires total contact cast

          5. Ankle brachial pressure index &lt; 0.7

          6. Has a local or systemic infection or local lymphangitis ≥ 0.5 cm

          7. Has any 1 of the following (only 1 of the 2 tests is required):

               1. A monophasic or biphasic flow (with loss of reverse flow) in the artery of the
                  foot with the target ulcer via doppler waveform analysis of the dorsalis pedis
                  and posterior tibial arteries

               2. Transcutaneous oxygen pressure (TcPO2) at the foot &lt;40 mgHg

          8. Presence of active malignant or benign tumor of any kind, (with the exception to
             nonmelanoma skin cancer as per investigator's discretion)

          9. Congestive heart failure (New York Heart Association class II-IV)

         10. Coronary heart disease with ST segment elevation myocardial infarction or coronary
             artery bypass graft or percutaneous transluminal coronary angioplasty within the last
             6 months

         11. Active osteomyelitis of the foot with the target ulcer detected by x-ray, CT scan, or
             MRI

         12. Active connective tissue disease

         13. Acute or chronic Charcot's neuro-arthropathy as determined by clinical and/or
             radiographic examination

         14. Active treatment with systemic corticosteroids or topical corticosteroids (for
             treatment of the target ulcer or any area of the foot). This does not include inhaled
             corticosteroids used for conditions other than treating the target ulcer or any area
             of the foot. Wash out period for systemic corticosteroids is 14 days for inclusion in
             this study. Wash out period for topical corticosteroids (for treatment of the target
             ulcer or any area of the foot) is 14 days for inclusion in the study)

         15. Active treatment with systemic antibiotics (wash out period for systemic antibiotics
             is 7 days for the inclusion in the study)

         16. Previous or current radiation therapy to the distal lower extremity or likelihood to
             receive this therapy during study participation

         17. Pregnant or nursing mothers

         18. Uncontrolled anemia (hemoglobin &lt; 10 g/dL in females and &lt; 12 g/dL in males)

         19. Estimated glomerular filtration rate &lt; 25 mL/min

         20. Poor nutritional status, defined as an albumin &lt; 25 g/L (&lt; 2,500 mg/dl)

         21. Significant peripheral edema as per investigator's discretion

         22. Known inability or unavailability of a patient to complete required study visits
             during study participation

         23. A psychiatric condition (e.g., suicidal ideation) or chronic alcohol or drug abuse
             problem, determined from the patient's medical history, which, in the opinion of the
             investigator, may pose a threat to patient compliance

         24. Use of a platelet-derived growth factor within 28 days before screening

         25. Use of any investigational drug or therapy within 28 days before screening

         26. Has any other factor which may, in the opinion of the investigator, compromise
             participation and/or follow-up in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>New Hope Podiatry Group, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integral - Clinical Trials Solutions</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Direct Helpers Research Center</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nirvana Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33193</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acclaim Bone &amp; Joint</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Futuro Clinical Trials, LLC</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre podiatrique et soins des plaies</name>
      <address>
        <city>Boucherville</city>
        <state>Quebec</state>
        <zip>J4B 5E4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinexpert Kft. - Kaszasdulo utca 5.</name>
      <address>
        <city>Budapest</city>
        <zip>1033</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strazsahegy Medicina Bt., Zrinyi utca 226</name>
      <address>
        <city>Budapest</city>
        <zip>1171</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shrey Hospital Pvt Ltd</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parul Sevashram Hospitals</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>390020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anand Multispecialty Hospital</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>390016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Convenient Hospitals Ltd., CHL - Hospitals</name>
      <address>
        <city>Indore</city>
        <state>Madhya Pradesh</state>
        <zip>452008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KLEs Dr. Prabakar Kore Hospital and Medical Research Center</name>
      <address>
        <city>Belgaum</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peoples College of Medical Science and Research Centre</name>
      <address>
        <city>Bhopal</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marwari Hospital and Research Centre</name>
      <address>
        <city>Guwahati</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surakshaka MultiSpecialty and Diabetes Hospital</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KRM Hospital and Research Center</name>
      <address>
        <city>Lucknow</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanjay Gandhi Postgraduate Institute of Medical Sciences</name>
      <address>
        <city>Lucknow</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fortis Hospital</name>
      <address>
        <city>Mohali</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K R Hospital and Research Institute</name>
      <address>
        <city>Mysore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Supe Heart and Diabetes Hospital and Research Centre</name>
      <address>
        <city>Nashik</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Batra Hospital and Medical Research Center</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aman Hospital and Research Centre</name>
      <address>
        <city>Vadodara</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anu Hospitals, Kovelamudivara Street</name>
      <address>
        <city>Vijayawada</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Medycyny Wsi - oddz diabetologii ul. Jaczewskiego 2, 20-090 Lublin, Poland</name>
      <address>
        <city>Lublin</city>
        <state>Jaczewskiego</state>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ MED ART. Poradnie Specjalistyczne Ks. Wladyslawa 27, 44-240 Zory, Poland</name>
      <address>
        <city>Zory</city>
        <state>Wladyslawa 27</state>
        <zip>44-240</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lubuskie Centrum Diabetologii UI.</name>
      <address>
        <city>Budziszynek</city>
        <state>Zielon</state>
        <zip>20 65-945</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MIKOMED Sp. z o.o. ul.</name>
      <address>
        <city>Łódź .</city>
        <state>Łódź .Pługowa</state>
        <zip>51 94-238</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 26, 2016</study_first_submitted>
  <study_first_submitted_qc>January 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2016</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetic foot ulcer</keyword>
  <keyword>diabetic complications</keyword>
  <keyword>diabetes</keyword>
  <keyword>wound healing</keyword>
  <keyword>Granexin gel</keyword>
  <keyword>FirstString Research</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

